Skip to main content Help with accessibility Skip to main navigation

October 2023 updates to the website

The website has now been updated following October's LSCMMG

The following guidelines have been added/updated:

Free of charge (FOC) medicines schemes – national policy recommendations for local systems - Updated

Restless legs guidance - Update to follow in November

Melatonin prescribing information sheet and Melatonin position statement - removed and replaced with Melatonin pathway (children)

The following medicines have been updated following the Commissioning Resource Group (CRG) meeting:

Brimonidine gel - Symptomatic treatment of moderate to severe facial erythema of rosacea in adult patients

Ibandronic acid Tablets - adjuvant treatment of early breast cancer in postmenopausal women with a high risk of recurrence (unlicensed indication)

Flupentixol dihydrochloride - Treatment of schizophrenia and psychoses

Fluoride (sodium) 1.1%toothpaste - Treatment of head and neck cancer patients who have had surgery, radiotherapy and/or chemotherapy

Bempedoic acid with ezetimibe - for treating primary hypercholesterolaemia or mixed dyslipidaemia (NICE TA694)

Cenobamate - Treating focal onset seizures in epilepsy (NICE TA753)

Melatonin - Multiple indications in children (see entry for all indications listed)

The following Items will be updated and added to the website following the next Commissioning Resource Group (CRG) Meeting:

Bempedoic acid (without ezetimibe) - Treatment of primary hypercholesterolaemia or mixed dyslipidaemia